Lahat G, Lubezky N, Gerstenhaber F, Nizri E, Gysi M, Rozenek M, Goichman Y, Nachmany I, Nakache R, Wolf I, Klausner J M
Department of Surgery, Tel Aviv Sourasky Medical Center, 6th Weitzman St., Tel Aviv, Israel.
Sackler Faculty of Medicine, The Nicholas and Elizabeth Cathedra of Experimental Surgery, Tel Aviv University, Tel Aviv, Israel.
World J Surg Oncol. 2016 Sep 29;14(1):254. doi: 10.1186/s12957-016-0983-5.
We evaluated the prognostic significance and universal validity of the total number of evaluated lymph nodes (ELN), number of positive lymph nodes (PLN), lymph node ratio (LNR), and log odds of positive lymph nodes (LODDS) in a relatively large and homogenous cohort of surgically treated pancreatic ductal adenocarcinoma (PDAC) patients.
Prospectively accrued data were retrospectively analyzed for 282 PDAC patients who had pancreaticoduodenectomy (PD) at our institution. Long-term survival was analyzed according to the ELN, PLN, LNR, and LODDS.
Of these patients, 168 patients (59.5 %) had LN metastasis (N1). Mean ELN and PLN were 13.5 and 1.6, respectively. LN positivity correlated with a greater number of evaluated lymph nodes; positive lymph nodes were identified in 61.4 % of the patients with ELN ≥ 13 compared with 44.9 % of the patients with ELN < 13 (p = 0.014). Median overall survival (OS) and 5-year OS rate were higher in N0 than in N1 patients, 22.4 vs. 18.7 months and 35 vs. 11 %, respectively (p = 0.008). Mean LNR was 0.12; 91 patients (54.1 %) had LNR < 0.3. Among the N1 patients, median OS was comparable in those with LNR ≥ 0.3 vs. LNR < 0.3 (16.7 vs. 14.1 months, p = 0.950). Neither LODDS nor various ELN and PLN cutoff values provided more discriminative information within the group of N1 patients.
Our data confirms that lymph node positivity strongly reflects PDAC biology and thus patient outcome. While a higher number of evaluated lymph nodes may provide a more accurate nodal staging, it does not have any prognostic value among N1 patients. Similarly, PLN, LNR, and LODDS had limited prognostic relevance.
我们在一个相对较大且同质化的接受手术治疗的胰腺导管腺癌(PDAC)患者队列中,评估了评估淋巴结总数(ELN)、阳性淋巴结数(PLN)、淋巴结比率(LNR)和阳性淋巴结对数比值(LODDS)的预后意义及普遍有效性。
对在我们机构接受胰十二指肠切除术(PD)的282例PDAC患者的前瞻性积累数据进行回顾性分析。根据ELN、PLN、LNR和LODDS分析长期生存情况。
这些患者中,168例(59.5%)有淋巴结转移(N1)。ELN和PLN的平均值分别为13.5和1.6。淋巴结阳性与更多的评估淋巴结数量相关;ELN≥13的患者中61.4%发现有阳性淋巴结,而ELN<13的患者中这一比例为44.9%(p = 0.014)。N0患者的中位总生存期(OS)和5年OS率高于N1患者,分别为22.4个月对18.7个月以及35%对11%(p = 0.008)。平均LNR为0.12;91例患者(54.1%)的LNR<0.3。在N1患者中,LNR≥0.3与LNR<0.3的患者中位OS相当(16.7个月对14.1个月,p = 0.950)。在N1患者组中,LODDS以及各种ELN和PLN临界值均未提供更多的鉴别信息。
我们的数据证实,淋巴结阳性强烈反映了PDAC生物学特性,进而反映患者预后。虽然更多的评估淋巴结数量可能提供更准确的淋巴结分期,但在N1患者中它没有任何预后价值。同样,PLN、LNR和LODDS的预后相关性有限。